A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is the first study in which TAK-441 is administered to humans. The patient population
will consist of adults aged 18 or older who have advanced nonhematologic malignancies and for
whom standard treatment is no longer effective or does not offer curative or life-prolonging
potential. Following completion of the dose escalation study, patients will be enrolled as
part of 2 expansion cohorts.